From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Staff Editor 2 · · 40s
Pfizer Q3 Earnings Beat
Pfizer reports stronger-than-expected Q3 FY26 earnings and raises full-year guidance.
In brief
Pfizer reports stronger-than-expected Q3 FY26 earnings and raises full-year guidance. Pfizer's Q3 FY26 earnings per share beat estimates at $0.87, with adjusted revenue of $16.58 billion and raised full-year 2026 revenue guidance to $62.0-$64.0 billion. Originally reported by Alphastreet - Earnings Decoded. Market…
Q3 Financial Results
Pfizer reported stronger-than-expected third-quarter earnings for fiscal 2026 with revenue of $16.58 billion, slightly down from the prior-year quarter.
Earnings Per Share
Adjusted earnings per share reached $0.87, beating analyst estimates, while reported net income declined to $3.24 billion.
Full-Year Guidance
Pfizer raised its full-year 2026 revenue guidance by $1.5 billion to $62.0-$64.0 billion and narrowed adjusted earnings per share guidance to $2.95-$3.05.
The main idea
Pfizer's Q3 FY26 earnings per share beat estimates at $0.87, with adjusted revenue of $16.58 billion and raised full-year 2026 revenue guidance to $62.0-$64.0 billion.
